By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Accelr8 today announced an investment group plans to invest up to $35 million into the company to support further development and commercialization of its BACcel platform.

In conjunction with the investment, one member of the investment group will become Accelr8's CEO.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.